Lexeo Therapeutics, Inc. (LXEO)
| Market Cap | 267.39M -59.5% |
| Revenue (ttm) | n/a |
| Net Income | -105.28M |
| EPS | -1.27 |
| Shares Out | 82.78M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 37,573,112 |
| Open | 3.550 |
| Previous Close | 2.870 |
| Day's Range | 3.000 - 4.300 |
| 52-Week Range | 2.550 - 10.990 |
| Beta | 1.65 |
| Analysts | Strong Buy |
| Price Target | 25.11 (+677.4%) |
| Earnings Date | Nov 16, 2026 |
About LXEO
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical tr... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 9 analysts, the average rating for LXEO stock is "Strong Buy." The 12-month stock price target is $25.11, which is an increase of 677.40% from the latest price.
News
Lexeo Therapeutics price target raised to $42 from $24 at Raymond James
Raymond James raised the firm’s price target on Lexeo Therapeutics (LXEO) to $42 from $24 and keeps a Strong Buy rating on the shares. The LX2020 12-month data showed substantial…
Lexeo Therapeutics price target raised to $37 from $23 at Cantor Fitzgerald
Cantor Fitzgerald raised the firm’s price target on Lexeo Therapeutics (LXEO) to $37 from $23 and keeps an Overweight rating on the shares. Lexeo reported Phase 1/2 interim data for…
Lexeo Therapeutics Earnings Call Transcript: Q3 2026
LX2020 showed substantial reductions in NSVT and PVC burden, alongside functional and patient-reported improvements. FDA feedback supports planning a 60–80-patient pivotal study for accelerated approval, targeted to begin in H2 2027.
Lexeo Therapeutics Earnings release: Q3 2026
Lexeo Therapeutics released its Q3 2026 earnings on November 16, 2026, summarizing the period's financial results.
Lexeo Therapeutics Quarterly report: Q3 2026
Lexeo Therapeutics has published its Q3 2026 quarterly earnings report on November 16, 2026.
Lexeo Therapeutics Slides: Q3 2026
Lexeo Therapeutics has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on November 16, 2026.
Lexeo Therapeutics announces interim data from HEROIC-PKP2 trial
Lexeo Therapeutics (LXEO) announced interim data from the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy. Across ten participants, incl...
Lexeo Therapeutics Announces Positive Interim Phase I/II Data and Regulatory Update for LX2020 in PKP2 Arrhythmogenic Cardiomyopathy and Reports Third Quarter 2026 Financial Results
Participants in high-dose cohorts achieved 80% mean reduction in non-sustained ventricular tachycardia and 44% mean reduction in premature ventricular contractions at latest assessment LX2020 generall...
Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026
NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced it...
Lexeo Therapeutics to Present Multiple Oral and Poster Presentations at Key Scientific Conferences in November
Presentations at AHA to highlight Lexeo's cardiovascular gene therapy pipeline, including preclinical programs in desmoplakin and TNNI3 cardiomyopathies New LX2006 data to be presented at ICAR demonst...
Lexeo Therapeutics Registration statement: Registration filing
Lexeo Therapeutics filed a registration statement on October 29, 2026, providing details about a securities offering with the SEC.
Lexeo Therapeutics files $300M mixed securities shelf
07:37 EDT Lexeo Therapeutics (LXEO) files $300M mixed securities shelf
Lexeo Therapeutics Transcript: Investor update
LX2020 is designed to address PKP2 ACM’s underlying biology, with NSVT positioned as a key clinical measure alongside PVCs and broader outcomes. Additional data and a regulatory update are expected this quarter; management cited durable arrhythmia reduction and favorable safety as central to the program’s potential.
Lexeo Therapeutics Transcript: Chardan's 10th Annual Healthcare Conference
LX2006’s phase III readout is expected in 2H 2027, with a BLA filing planned for H1 2028. Q4 PKP2 data and regulatory updates are anticipated, while SUNRISE-FA 2 enrollment is supported by CLARITY-FA.
Lexeo Therapeutics to Host Educational Event Focused on Clinical Endpoints and Outcome Measures in PKP2-ACM
NEW YORK, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced tha...
Lexeo Therapeutics to Participate in the Chardan Healthcare Conference
NEW YORK, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced tha...
Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)
Oral presentation will highlight previously reported data demonstrating early stabilization or improvement in mFARS scores among LX2006-treated participants compared with propensity-matched control co...
Lexeo Therapeutics Transcript: Stifel 2026 Virtual Cardiometabolic Forum
Lead FA cardiomyopathy program is in a pivotal trial with data expected in 2027, complemented by new brain-targeted assets from a recent acquisition. PKP2 arrhythmogenic cardiomyopathy program shows promising efficacy and safety, with key data and regulatory updates due late 2026. Cash reserves exceed $230 million, supporting operations into 2028.
Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia
NEW YORK, Sept. 23, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, will provide Lexeo Therapeutics, Inc. (...
Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum
NEW YORK, Sept. 23, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO) a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced th...
Lexeo Therapeutics Transcript: M&A announcement
The acquisition of Mantle Therapeutics and new research collaborations significantly expand the FA platform, adding CNS-targeted and diversified therapeutic modalities. The $21.3M deal aims for comprehensive disease coverage, with prioritization updates and IND submission planned for 2027.
Lexeo Therapeutics Press release: M&A announcement
Lexeo Therapeutics issued a press release on September 22, 2026, disclosing material business information to investors.
Lexeo Therapeutics Slides: M&A announcement
Lexeo Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 22, 2026.
Lexeo Therapeutics enter into agreement to acquire Mantle Therapeutics
Lexeo Therapeutics (LXEO) announced a series of strategic transactions to expand its presence in Friedreich ataxia, including the signing of a definitive agreement to acquire Mantle Therapeutics and t...
Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia
Acquisition of Mantle Therapeutics will add multiple new modalities designed to increase or replace frataxin in the brain Collaborations launched to evaluate gene therapy sequential dosing following ...